Pictet Biotech Class I - Income (GBP)

In some cases the ongoing savings are provided by our loyalty bonus. Loyalty bonuses are tax-free in an ISA or SIPP. However, they may be subject to tax in a Fund & Share Account which would, in effect, reduce their value and increase the net ongoing charge.

Please remember past performance is not a guide to future returns. Where no data is shown, figures are not available. This information is provided to help you choose your own investments, remember they can fall as well as rise in value so you may not get back the original amount invested.

The Wealth Shortlist features funds our analysts believe have the potential to outperform their peers over the long term. If a fund is not on the Shortlist, this is not a recommendation to sell; however, if you are thinking of adding to your investments, we believe the Wealth Shortlist is a good place to start. View funds on the Wealth Shortlist »

The sub-fund seeks capital growth by investing at least two-thirds of its total assets in the shares of particularly innovative companies operating in medical biotechnology. The investment universe is not restricted to a specific geographical zone. However, given the particularly innovative nature of the pharmaceutical industry in North America and Europe, the vast majority of investments will be made in this zone.

Income paid:	Annually
Type of payment:	No income
Ex-dividend date:	7 December 2024
Payment date:	14 December 20244

This data is provided by Broadridge. HL accepts no responsibility for its accuracy and you should independently check data before making any investment decision. All yields are variable and not guaranteed. There is currently no yield information available for this fund.